Akebia Therapeutics Announces September 2021 Investor Conference Schedule
Get Alerts AKBA Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Sept. 1, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following schedule of investor conferences:
AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" />
- Morgan Stanley 19th Annual Global Healthcare Conference Virtual fireside chat at 2:45 p.m. ET on September 9
- H.C. Wainwright 23rd Annual Global Investment Conference On-demand presentation available at 7:00 a.m. ET on September 13
- Cantor Fitzgerald Virtual Global Healthcare Conference 2021 Virtual presentation at 2:00 p.m. ET on September 27
Where applicable, live webcasts of Akebia's fireside chats and presentations will be made available on the Investors section of the Company's website at https://ir.akebia.com .
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact Kristen K. Sheppard, Esq. [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-announces-september-2021-investor-conference-schedule-301366758.html
SOURCE Akebia Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dystopian Thriller Examines Individual Freedom and Authoritarianism
- Avulux Granted FDA De Novo Authorization, Creating the First Lens Classification for Migraine-Associated Light Sensitivity
- Tysons, Virginia Plastic Surgeon Dr. Munique Maia Introduces the MAIA Method for Deep Plane Facelift and Comprehensive Facial Rejuvenation
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Cantor Fitzgerald, Morgan Stanley, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share